GENE ONLINE|News &
Opinion
Blog

2022-10-03| Policy

Novartis Ordered to Pay $177.8 million to Plexxikon for Patent Infringements

by Max Heirich
Share To

A federal court in California ordered Novartis to pay Daiichi Sankyo’s research and development subsidiary, Plexxikon, $177.8 million. The ruling holds that BRAF inhibitor Tafinlar® infringes two of Plexxikon’s cancer drug patents. This ruling comes just a few months after the five-year anniversary of the case’s filing. 

Related Article: Moderna’s Lawsuit Against Pfizer/BioNTech: What Does This Mean for Their Vaccine’s future?

The Infringed Patents

The development for the two infringed patents, 9,469,640 and 9,844.539, began in 2005. Both parents secure the rights to compounds reducing cancer cell growth. In collaboration with Roche, Plexxikon used the patents for the creation of Zelboraf, a melanoma drug. Zelboraf won FDA approval in 2011, eleven years before Novartis’ Tafinlar.

Plexxikon filed a lawsuit against Novartis for alleged infringement of their two patents in 2017. Throughout the suite, Novartis argued that Plexxikon’s two patients were invalid, citing three GSK compounds that preceded them.

However, in July of this year, a jury found that Novartis had not proved that Plexxikon’s patents were invalid. In addition, their verdict ruled Novartis engaged in ‘willing infringement.’

Ordered to pay restitution, Novartis appealed the decision to the U.S. District Court for the Northern District of California.

The Federal Court’s Ruling

The federal court released its ruling, shooting down Novartis’ attempt at a new trial. However, it wasn’t a total loss for the Swiss company. The appeal succeeded in switching the ruled ‘willful infringement’ of Novartis to ‘unintentional infringement.’ This simple change secured Novartis against the potential tripling of their payment to Plexxikon.

However, the original fine still stands, totaling $177.8 million in payment to Plexxikon along with an additional 9% royalty on U.S. sales of Tafinlar. However, the parent company will scoop the awarded money due to Daiichi’s closure of Plexxikon earlier this year. In a press release, Daiichi stated that any financial impact of the decision is under evaluation. 

In the last fiscal year alone, Novartis sold $1.5 billion of Tafinlar. With Plexikkon’s two patents expiring in 2028, Novartis’ payments could end up totaling millions, if not billions, of dollars. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
GeneOnline’s Pick – Top 10 Global Industry News Stories in 2023 (Part 2)
2024-01-15
LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top